

Reissue Application of  
U.S. Patent No. 5,637,310  
Atty. Docket No. 14509-C2 RI

1993, now U.S. Patent No. 5,496,556 ("the '556 patent"). However, omitted from that cross-reference was citation of the fact that the '556 patent itself was a continuation of the original application in the series, Serial No. 544,709, filed June 27, 1990, now U.S. Pat. No. 5,300,294 ("the '294 patent"). In this Preliminary Amendment, the specification has been amended to expressly cross-reference the application, Serial No. 544,709, which issued as the '294 patent. There has been no change in the claims from claims 1-2 as issued.

For the foregoing reasons, Patent Owner respectfully submits that claims 1-2 of this application are in condition for allowance. The Examiner is advised that the '310 patent is involved in pending Interference No. 104,646, and that addition of this reissue application to the interference is being sought. Early notification that this reissue application is in condition for allowance is respectfully requested.

If there are any fees due in connection with the filing of this Preliminary Amendment not already accounted for, please charge the fees to our Deposit Account No. 19-2570.

Respectfully Submitted,

September 13, 2001  
Date

Wayne J. Dustman  
Wayne J. Dustman  
Registration No. 33,870  
Attorney for GlaxoSmithKline

GlaxoSmithKline  
709 Swedeland Road  
P.O. Box 1539  
King of Prussia, PA 19406-0939